Baxter International Inc (BAX) Holdings Boosted by First National Trust Co

First National Trust Co grew its position in Baxter International Inc (NYSE:BAX) by 25.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,995 shares of the medical instruments supplier’s stock after purchasing an additional 11,722 shares during the quarter. First National Trust Co’s holdings in Baxter International were worth $4,471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of BAX. FMR LLC boosted its position in shares of Baxter International by 25.6% in the second quarter. FMR LLC now owns 28,637,027 shares of the medical instruments supplier’s stock worth $2,114,558,000 after purchasing an additional 5,845,720 shares during the period. Voya Investment Management LLC boosted its position in shares of Baxter International by 411.6% in the second quarter. Voya Investment Management LLC now owns 3,411,849 shares of the medical instruments supplier’s stock worth $251,931,000 after purchasing an additional 2,745,012 shares during the period. Morgan Stanley boosted its position in shares of Baxter International by 107.8% in the second quarter. Morgan Stanley now owns 2,873,253 shares of the medical instruments supplier’s stock worth $212,161,000 after purchasing an additional 1,490,287 shares during the period. Standard Life Aberdeen plc boosted its position in shares of Baxter International by 77.2% in the second quarter. Standard Life Aberdeen plc now owns 2,596,870 shares of the medical instruments supplier’s stock worth $191,753,000 after purchasing an additional 1,131,691 shares during the period. Finally, SPF Beheer BV bought a new position in shares of Baxter International during the second quarter worth $53,405,000. Institutional investors and hedge funds own 83.08% of the company’s stock.

A number of equities analysts recently weighed in on the stock. ValuEngine lowered shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Thursday. Barclays assumed coverage on shares of Baxter International in a research report on Monday, October 15th. They set an “underweight” rating and a $73.00 target price for the company. Morgan Stanley upped their target price on shares of Baxter International from $68.00 to $75.00 and gave the stock an “underweight” rating in a research report on Thursday, October 11th. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $87.00 target price for the company in a research report on Tuesday, September 25th. Finally, Argus restated a “hold” rating on shares of Baxter International in a research report on Tuesday, September 4th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the stock. Baxter International currently has an average rating of “Hold” and an average price target of $77.77.

Shares of NYSE:BAX opened at $62.51 on Thursday. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.62 and a quick ratio of 2.00. Baxter International Inc has a fifty-two week low of $61.05 and a fifty-two week high of $78.38. The firm has a market cap of $36.68 billion, a P/E ratio of 25.21, a P/E/G ratio of 1.86 and a beta of 0.77.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Wednesday, October 31st. The medical instruments supplier reported $0.80 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.06. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.79 billion. Baxter International had a net margin of 8.29% and a return on equity of 16.63%. Baxter International’s revenue was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.64 earnings per share. Research analysts anticipate that Baxter International Inc will post 2.98 earnings per share for the current year.

In related news, Director Carole J. Shapazian sold 5,400 shares of the company’s stock in a transaction on Wednesday, August 8th. The shares were sold at an average price of $72.97, for a total transaction of $394,038.00. Following the sale, the director now owns 15,248 shares of the company’s stock, valued at $1,112,646.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Giuseppe Accogli sold 17,647 shares of the company’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $77.27, for a total transaction of $1,363,583.69. Following the sale, the senior vice president now directly owns 59,452 shares in the company, valued at approximately $4,593,856.04. The disclosure for this sale can be found here. 0.05% of the stock is owned by corporate insiders.

Baxter International Profile

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Read More: What is a Stop Order?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply